These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

778 related articles for article (PubMed ID: 36849442)

  • 1. Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment.
    Tian H; Cao J; Li B; Nice EC; Mao H; Zhang Y; Huang C
    Bone Res; 2023 Feb; 11(1):11. PubMed ID: 36849442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.
    Zhu T; Han J; Yang L; Cai Z; Sun W; Hua Y; Xu J
    Front Immunol; 2022; 13():907550. PubMed ID: 35720360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.
    Ying H; Li ZQ; Li MP; Liu WC
    Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies.
    Liang H; Cui M; Tu J; Chen X
    Front Cell Dev Biol; 2024; 12():1394339. PubMed ID: 38915446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality.
    Yu L; Zhang J; Li Y
    Front Immunol; 2022; 13():871076. PubMed ID: 36311748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.
    Fan TM; Roberts RD; Lizardo MM
    Front Oncol; 2020; 10():13. PubMed ID: 32082995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.
    Chen C; Xie L; Ren T; Huang Y; Xu J; Guo W
    Cancer Lett; 2021 Mar; 500():1-10. PubMed ID: 33359211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment.
    Gao S; Yang X; Xu J; Qiu N; Zhai G
    ACS Nano; 2021 Aug; 15(8):12567-12603. PubMed ID: 34339170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma.
    Wu K; Yu B; Li D; Tian Y; Liu Y; Jiang J
    Front Oncol; 2022; 12():805978. PubMed ID: 35242707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone Microenvironment and Osteosarcoma Metastasis.
    Yang C; Tian Y; Zhao F; Chen Z; Su P; Li Y; Qian A
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Immune Microenvironments (TIMEs): Responsive Nanoplatforms for Antitumor Immunotherapy.
    Sui X; Jin T; Liu T; Wu S; Wu Y; Tang Z; Ren Y; Ni D; Yao Z; Zhang H
    Front Chem; 2020; 8():804. PubMed ID: 33094098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Immunotherapies for Osteosarcoma.
    Lu Y; Zhang J; Chen Y; Kang Y; Liao Z; He Y; Zhang C
    Front Oncol; 2022; 12():830546. PubMed ID: 35433427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapeutic strategies for spinal osteosarcomas.
    Anwar MA; El-Baba C; Elnaggar MH; Elkholy YO; Mottawea M; Johar D; Al Shehabi TS; Kobeissy F; Moussalem C; Massaad E; Omeis I; Darwiche N; Eid AH
    Semin Cancer Biol; 2020 Aug; 64():83-92. PubMed ID: 31152785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress and opportunities for immune therapeutics in osteosarcoma.
    Lettieri CK; Appel N; Labban N; Lussier DM; Blattman JN; Hingorani P
    Immunotherapy; 2016 Oct; 8(10):1233-44. PubMed ID: 27605071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction between osteosarcoma and other cells in the bone microenvironment: From mechanism to clinical applications.
    Zeng J; Peng Y; Wang D; Ayesha K; Chen S
    Front Cell Dev Biol; 2023; 11():1123065. PubMed ID: 37206921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated macrophages in osteosarcoma.
    Zhao Y; Zhang B; Zhang Q; Ma X; Feng H
    J Zhejiang Univ Sci B; 2021 Nov; 22(11):885-892. PubMed ID: 34783219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of aging/senescence-induced genes in osteosarcoma and predicting clinical prognosis.
    Lv Y; Wu L; Jian H; Zhang C; Lou Y; Kang Y; Hou M; Li Z; Li X; Sun B; Zhou H
    Front Immunol; 2022; 13():997765. PubMed ID: 36275664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of exosomal miR‑21 in the tumor microenvironment and osteosarcoma tumorigenesis and progression (Review).
    Wang S; Ma F; Feng Y; Liu T; He S
    Int J Oncol; 2020 May; 56(5):1055-1063. PubMed ID: 32319566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applying Osteosarcoma Immunology to Understand Disease Progression and Assess Immunotherapeutic Response.
    Pratt HG; Justin EM; Lindsey BA
    Adv Exp Med Biol; 2020; 1258():91-109. PubMed ID: 32767236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.